Cleveland Diagnostics

About Cleveland Diagnostics

Cleveland Diagnostics is focused on improving cancer decisions by offering novel and more accurate testing for early detection of cancer and assessing the risk of high-grade disease. Their mission is to provide simpler, clearer cancer diagnostics through innovative technology.

Products & Services

IsoPSA Test:A prostate cancer test that reduces unnecessary biopsies by up to 55% with higher sensitivity and specificity (2-3 times that of traditional PSA tests) to clarify the presence of aggressive cancer.

IsoClear Platform:A platform that measures structural differences in proteins to identify cancer cell biomarkers, enabling the development of affordable blood tests for clearer cancer diagnostics.

Specialties

Cancer Diagnostics Early Cancer Detection Prostate Cancer Testing Biomarker Analysis

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Growth Capital T: - FT: Growth Capital	A: 75000000 MR: - FA: $75M FAN: 75000000	D: 2024-01-17 FD: 2024-01-17	2 investors

Growth Capital Latest

2024-01-17

$75.0M

2 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Arnon Chait

Chief Executive Officer

A

Aimee Kestranek

Chief Operating Officer

B

Bob Rochelle

Chief Commercial Officer

M

Mark Stovsky

Chief Medical Officer

A

Andrew Summers

Chief Financial Officer

B

Boris Zaslavsky

Chief Scientific Officer Emeritus

View 8 more team members with Pro

Unlock Full Team Directory

Recent News